Published • loading... • Updated
Okami Medical Receives Expanded Indication for the LOBO Vascular Occluder
The expanded indication broadens embolization options for patients with pelvic venous disease and portal hypertension, officials said.
- On Wednesday, Oct. 7, 2026, the FDA granted Okami Medical an expanded indication for its LOBO Vascular Occlusion System, allowing use in peripheral veins for conditions like pelvic venous disease.
- Engineered with proprietary HDBRAID construction, the LOBO provides fast, predictable occlusion across various vessel anatomies, optimizing deliverability and stability for complex vascular conditions.
- Raj Pyne, FSIR of Rochester Regional Health, noted that previous embolization devices often faced "trackability issues" and "significant CT metallic artifact," which the expanded indication helps minimize.
- Harris Chengazi of Great Lakes Medical Imaging said, "In my experience, the LOBO has proven to be a rapid and reliable embolization platform," endorsing the system's clinical performance.
- Chief Executive Officer Drew Hykes said, "This venous indication expansion reflects Okami's continued investment in the peripheral embolization space," as the company aims to bring benefits to more patients.
Insights by Ground AI
13 Articles
13 Articles
Okami Medical Receives Expanded Indication for the LOBO Vascular Occluder
ALISO VIEJO, Calif., Oct. 7, 2026 /PRNewswire/ -- Okami Medical, a medical technology company developing novel vascular embolization solutions, announced today that the U.S. FDA has granted an expanded indication for its LOBO® Vascular Occlusion System. The expanded indication extends…
·Billings, United States
Read Full ArticleCoverage Details
Total News Sources13
Leaning Left1Leaning Right0Center11Last UpdatedBias Distribution92% Center
Bias Distribution
- 92% of the sources are Center
92% Center
C 92%
Factuality
To view factuality data please Upgrade to Premium
